IL‐12‐Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivoa
- 1 October 1996
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 795 (1), 284-293
- https://doi.org/10.1111/j.1749-6632.1996.tb52678.x
Abstract
Click on the article title to read more.This publication has 17 references indexed in Scilit:
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.The Journal of Experimental Medicine, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.The Journal of Experimental Medicine, 1996
- Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1995
- Activated T cells induce interleukin‐12 production by monocytes via CD40‐CD40 ligand interactionEuropean Journal of Immunology, 1995
- Paracrine Cytokine Adjuvants in Cancer ImmunotherapyAnnual Review of Immunology, 1995
- Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor AntigensScience, 1994
- T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin‐12 and interferon‐γ and is inhibited by transforming growth factor‐βEuropean Journal of Immunology, 1994
- Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivoEuropean Journal of Immunology, 1994
- Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cellsInternational Immunology, 1993
- Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes.The Journal of Experimental Medicine, 1989